Effects of metoclopramide on emesis in cats sedated with xylazine hydrochloride.
The prophylactic anti-emetic effect of five dosages of metoclopramide (0.2, 0.4, 0.6, 0.8 and 1mg/kg, IM) was evaluated against saline solution, both injected 1h before administration of xylazine in cats. Saline was administered to cats (day 0) followed by sequentially increasing dosages of metoclopramide at 1-week intervals. After xylazine injection, all cats were carefully observed to record the frequency of emesis and the time until onset of the first emetic episode. The onset of sedation in these cats was also studied. Prior treatment with each dosage of metoclopramide significantly reduced the frequency of emetic episodes (P<0.05). Metoclopramide administration prior to xylazine injection did not alter the time until onset of the first emetic episode at any of mentioned dosages, but significantly reduced the time until onset of sedation only at the dose of 1mg/kg. Metoclopramide may be used as a prophylactic anti-emetic in cats sedated with xylazine hydrochloride.
Kolahian
Saeed
S
Department of Basic Sciences, Faculty of Veterinary Medicine, University of Tabriz, Iran. skolahian@tabrizu.ac.ir
Jarolmasjed
Seyedhosein
S
D000818:Animals; D000932:Antiemetics / Q000008:administration & dosage*; D002371:Cat Diseases / Q000517:prevention & control*; D002415:Cats; D005260:Female; D006993:Hypnotics and Sedatives / Q000008:administration & dosage; D008297:Male; D008787:Metoclopramide / Q000008:administration & dosage*; D012965:Sodium Chloride / Q000008:administration & dosage; D013997:Time Factors; D014839:Vomiting / Q000517:prevention & control / Q000662:veterinary*; D014991:Xylazine / Q000008:administration & dosage
D000932:Antiemetics; D006993:Hypnotics and Sedatives; D014991:Xylazine; D012965:Sodium Chloride; D008787:Metoclopramide
Cancer. 1984 Mar 15;53(6):1432-9
6692333
J Vet Pharmacol Ther. 1981 Jun;4(2):93-6
7349332
Anesth Analg. 2004 Sep;99(3):734-739
15333403
Vet Med Small Anim Clin. 1973 Jul;68(7):741-4
4489766
Can J Physiol Pharmacol. 1990 Feb;68(2):230-6
2178747
Front Neuroendocrinol. 1994 Dec;15(4):301-20
7895890
Clin Tech Small Anim Pract. 1999 Feb;14(1):10-4
10193041
J Pain Symptom Manage. 1996 Mar;11(3):147-53
8851371
Cochrane Database Syst Rev. 2006 Jul 19;(3):CD004125
16856030
Am J Vet Res. 1989 Aug;50(8):1348-51
2571319
Eur J Cancer Clin Oncol. 1986 Oct;22(10):1199-203
3545851
Eur J Pharmacol. 1986 Nov 4;130(3):229-35
2878819
Am J Obstet Gynecol. 2002 May;186(5 Suppl Understanding):S256-61
12011897
Am J Vet Res. 2001 Aug;62(8):1218-21
11497441
N Engl J Med. 1981 Oct 15;305(16):905-9
7024807
Eur J Pharmacol. 1992 Dec 15;229(2-3):241-51
1362706
J Pain Symptom Manage. 2000 Jun;19(6):427-35
10908823
J Vet Pharmacol Ther. 2007 Aug;30(4):281-7
17610400
Neurosci Res. 1996 Nov;26(3):235-69
9121734
J Clin Oncol. 1984 Jul;2(7):782-7
6539812
Can J Physiol Pharmacol. 1985 Sep;63(9):1190-4
2996733
J Vet Pharmacol Ther. 1988 Dec;11(4):295-313
3062194
Support Care Cancer. 2002 Apr;10(3):231-6
11904788
J Am Vet Med Assoc. 1984 Oct 15;185(8):886-8
6501048
Eur J Cancer Clin Oncol. 1987 Jun;23(6):615-7
3308477
Trends Pharmacol Sci. 1988 Sep;9(9):334-41
3078093
Gan To Kagaku Ryoho. 2003 Jun;30(6):760-4
12852341
Am J Vet Res. 1982 Jun;43(6):1009-14
6125114
Br Med J (Clin Res Ed). 1984 Jun 23;288(6434):1879
6428589
J Pain Symptom Manage. 1995 Oct;10(7):521-6
8537694
Cephalalgia. 1998 Nov;18(9):593-604
9876882
J Exp Clin Cancer Res. 2003 Mar;22(1):17-22
12725317
Drugs. 1992 Mar;43(3):295-315
1374316